Dr. Edwin Stone, CEO of Cellular Origins, emphasizes that scalable manufacturing must support, not limit, development of safe and effective biological therapies like cell therapies while speaking at the 2026 ASGCT Annual Meeting.
Edwin Stone
Advertisement
Edwin Stone, PhD is CEO of Cellular Origins.
Articles by Edwin Stone
Cell therapy developers are prioritizing scalable manufacturing strategies alongside efficacy to support broader commercial deployment, notes Cellular Origins CEO Dr. Edwin Stone at the 2026 ASGCT Annual Meeting.
Advertisement
Latest Updated Articles
Advertisement
Advertisement